Impax Laboratories Inc (IPXL) Bucks Bearish Expectations

Impax Laboratories Inc (IPXL) plans to cut over 200 workers as part of its restructuring plan

Mar 9, 2016 at 2:56 PM
facebook twitter linkedin

Unlike one sector peer, Impax Laboratories Inc (NASDAQ:IPXL) is on a tear today, after the drugmaker's board of directors approved a restructuring plan. Expected to achieve an annualized cost savings of up to $27 million starting in 2017, the plan will include a workforce reduction upwards of 200 positions.

As alluded to, IPXL has put in a strong showing today, with the drug stock last seen 4.5% higher at $33.99. Historically speaking, this is unusual. The shares have surrendered more than one-fifth of their value in 2016, and late last month hit an annual low of $29.66.

Therefore, it comes as little surprise that Wall Street is in IPXL's bearish corner. In terms of options, short-term traders have gravitated toward puts relative to calls, as evidenced by the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.92 -- ranking in the 71st annual percentile.

Likewise, analysts and short sellers have taken a glass-half-empty approach. While short interest has decreased in recent reporting periods, nearly 12% of IPXL's float remains sold short. At the stock's typical trading levels, it would take over two weeks to cover these bearish bets.

Also, seven of nine analysts tracking Impax Laboratories Inc (NASDAQ:IPXL) have doled out a "hold" or worse rating. About the only sign of optimism among the brokerage crowd is the stock's average 12-month price target of $41.46, which stands at a nearly 23% premium to its current perch.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial


Special Offers from Schaeffer's Trading Partners